

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an annual general meeting of Innovative Pharmaceutical Biotech Limited (the “Company”) will be held at The Function Room 1–2, 2/F The Harbourview, 4 Harbour Road, Wanchai, Hong Kong on Friday, 29 August 2025 at 11:00 a.m. for the following purposes:

AS ORDINARY BUSINESS

1. To receive and adopt the audited financial statements and the reports of the directors (the “Director(s)”) and of the auditors (the “Auditors”) of the Company for the year ended 31 March 2025.
2.
 - (i) To re-elect Dr. Yeung Yung as an executive Director;
 - (ii) To re-elect Mr. Gao Yuan Xing as an executive Director;
 - (iii) To re-elect Mr. Tang Rong as an executive Director;
 - (iv) To re-elect Ms. Qi Shujuan as an executive Director;
 - (v) To re-elect Dr. Long Fan as an executive Director;
 - (vi) To re-elect Dr. Wu Ming as an executive Director;
 - (vii) To re-elect Mr. Zhang Shen as an executive Director;
 - (viii) To re-elect Mr. Zhang Yi as a non-executive Director;
 - (ix) To re-elect Ms. Chen Weijun as an independent non-executive Director;

- (x) To re-elect Dr. Xia Tingkang, Tim as an independent non-executive Director;
 - (xi) To re-elect Ms. Sun Sizheng as an independent non-executive Director; and
 - (xii) To authorise the board of Directors (the “Board”) to fix the Directors’ remuneration.
3. To re-appoint SFAI (HK) CPA Limited as the Auditors and to authorise the Board to fix their remuneration.

AS SPECIAL BUSINESS

4. To consider and, if thought fit, pass with or without amendments, the following resolutions as an ordinary resolution:

“THAT

- (a) subject to paragraph (c) of this resolution, the exercise by the Directors during the Relevant Period (as defined in paragraph (d) below) of all the powers of the Company to allot, issue and otherwise deal with additional shares (“Shares”) in the share capital of the Company or securities convertible into the Shares, or options, warrants or similar rights to subscribe for any Shares or such convertible securities, and to make, grant, sign or execute offers, agreements or options, deeds and other documents which would or might require the exercise of such powers, subject to and in accordance with all applicable laws, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) of this resolution shall authorise the Directors during the Relevant Period to make, grant, sign or execute offers, agreements or options, deeds and other documents which would or might require the exercise of such powers after the end of the Relevant Period;
- (c) the total number of shares of the Company allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) and issued by the Directors pursuant to the approval in paragraph (a) of this resolution, otherwise than pursuant to:
 - (i) a Rights Issue (as defined in paragraph (d) below); or

- (ii) any issue of the Shares upon the exercise of rights of subscription or conversion attaching to any warrants of the Company or any securities which are convertible into the Shares; or
- (iii) the exercise of any option under any share option scheme of the Company or similar arrangement for the time being adopted or rights to acquire the Shares; or
- (iv) any issue of the Shares as scrip dividends or under similar arrangement providing for the allotment of the Shares in lieu of the whole or part of a dividend on the Shares in accordance with the bye-laws of the Company in force from time to time; or
- (v) a specific authority granted by the shareholders of the Company.

shall not exceed 20 per cent. of the total number of the shares of the Company in issue as at the date of passing of this resolution, and the said approval shall be limited accordingly;

- (d) for the purpose of this resolution:

“Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company; or
- (ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or the applicable laws of Bermuda to be held; or
- (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting prior to the next annual general meeting of the Company; and

“Rights Issue” means an allotment, issue or grant of the Shares pursuant to an offer of the Shares open for a period fixed by the Directors to the holders of the Shares whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of such Shares as at that date (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any

restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company).”

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“THAT

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as defined below) of all powers of the Company to purchase Shares in the share capital of the Company or securities convertible into the Shares on The Stock Exchange of Hong Kong Limited (“Stock Exchange”) or on any other exchange on which the securities of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose (“Recognised Stock Exchange”), subject to and in accordance with the applicable laws of Bermuda and the requirements of the Rules Governing the Listing of Securities on the Stock Exchange or those of any other Recognised Stock Exchange as amended from time to time, be and the same is hereby generally and unconditionally approved;
- (b) the total number of the Shares and securities convertible into the Shares which may be bought back by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period shall not exceed 10 per cent. of the total number of the shares of the Company in issue as at the date of passing of this resolution, and the approval pursuant to paragraph (a) of this resolution shall be limited accordingly;
- (c) for the purpose of this resolution, “Relevant Period” means the period from the date of passing of this resolution until whichever is the earliest of:
 - (i) the conclusion of the next annual general meeting of the Company; or
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or the applicable laws of Bermuda to be held; or
 - (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting prior to the next annual general meeting of the Company.”

6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT** subject to the passing of the resolutions numbered 4 and 5 above, the general mandate granted to the Directors to exercise the powers of the Company to allot, issue and otherwise deal with the share capital of the Company pursuant to the resolution numbered 4 be and the same is hereby extended by the addition to the total number of Shares which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to such general mandate of an amount representing the total number of Shares bought back by the Company pursuant to the resolution numbered 5 provided that such amount shall not exceed 10 per cent of the total number of Shares in issue as at the date of passing of this resolution.”

7. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT**

- (a) the authorised share capital of the Company be increased from (i) HK\$500,000,000 divided into 50,000,000,000 shares of HK\$0.01 each to (ii) HK\$1,200,000,000 divided into 120,000,000,000 shares of HK\$0.01 each, by the creation of an additional 70,000,000,000 shares of HK\$0.01 each (in aggregate HK\$700,000,000) (the “Proposed Increase in Authorised Share Capital”), so that following the Proposed Increase in Authorised Share Capital, the authorised share capital of the Company shall become HK\$1,200,000,000 divided into 120,000,000,000 shares of HK\$0.01 each, and each such new share, upon issue and fully paid, shall rank pari passu in all respects with the existing issued shares and have the rights and privileges and be subject to the provisions contained in the memorandum of association and bye-laws of the Company; and
- (b) any Director be and is hereby authorised to do all such acts and things and execute all such documents as may be necessary, desirable or expedient for the purpose of, or in connection with the implementation of or giving effect to the Proposed Increase in Authorised Share Capital, including without limitation to attend to any necessary registrations and filings for and on behalf of the Company in accordance with the relevant requirements of the applicable laws, rules and regulations in Bermuda and Hong Kong.”

SPECIAL RESOLUTION

8. To consider and, if thought fit, pass, with or without amendments, the following resolution as a special resolution:

“THAT

- (a) subject to and conditional upon the approval of the Registrar of Companies in Bermuda being obtained, the English name of the Company be changed from “Innovative Pharmaceutical Biotech Limited” to “Starcoin Group Limited”, and the Chinese name of “星太鏈集團有限公司” to be adopted as the secondary name of the Company in place of the existing name of “領航醫藥及生物科技有限公司” (the “Proposed Change of Company Name”), with effect from the date on which the new English name being entered in the register maintained by the Registrar of Companies in Bermuda; and
- (b) any Directors be and is hereby authorised to do all such acts and things and execute all such documents as may be necessary, desirable or expedient for the purpose of, or in connection with the implementation of or giving effect to the Proposed Change of Company Name, including without limitation to attend to any necessary registrations and filings for and on behalf of the Company in accordance with the relevant requirements of the applicable laws, rules and regulations in Bermuda and Hong Kong.”

By order of the Board
Innovative Pharmaceutical Biotech Limited
Yeung Yung
Chairman

Hong Kong, 31 July 2025

Registered Office:
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Principal Place of Business in Hong Kong:
Unit No. 2002, 20/F
On Hong Commercial Building
145 Hennessy Road
Wan Chai
Hong Kong

Notes:

- (1) A member of the Company entitled to attend and vote at the aforesaid meeting is entitled to appoint one or (if holding two or more Shares) more proxies to attend and vote in his stead. A proxy need not be a member of the Company. If more than one proxy is appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed.
- (2) To be valid, the form of proxy together with any power of attorney or other authority under which it is signed or a notarially certified copy of that power of attorney or other authority must be deposited with the branch share registrar and transfer agent of the Company in Hong Kong, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 48 hours before the time fixed for holding the meeting or any adjournment thereof.
- (3) When there are joint holders of any Shares, any one of such persons may vote at the meeting either personally or by proxy in respect of such Share as if he were solely entitled thereto; but if more than one of such joint holders are present at the meeting jointly or by proxy, then one of the said persons so present whose name stands first on the register of members of the Company shall alone be entitled to vote in respect of such Share.
- (4) Completion and return of the form of proxy will not preclude members from attending and voting at the aforesaid meeting and in such event, the form of proxy shall be deemed to be revoked.
- (5) For determining the entitlement to attend and vote at the annual general meeting of the Company, the register of members of the Company will be closed from 26 August 2025, Tuesday to 29 August 2025, Friday, both days inclusive, during which period no transfer of Shares will be registered. The record date for determining the eligibility of the shareholders to attend and vote at the Annual General Meeting will be 29 August 2025. All transfers of Shares accompanied by the relevant share certificates and properly completed transfer forms must be lodged with the branch share registrar and transfer agent of the Company in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on 25 August 2025.
- (6) If Typhoon Signal No. 8 or above is hoisted or remains hoisted at 9:00 a.m. on the date of the Annual General Meeting, the Annual General Meeting will be postponed. The Company will post an announcement on the Company's website at <http://www.ipb.asia/> and the Stock Exchange's website at www.hkexnews.hk to notify shareholders of the Company of the date, time and place of the rescheduled Annual General Meeting.

As at the date of this notice, the Board comprises Dr. Yeung Yung (Chairman and executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Qi Shujuan (executive Director), Dr. Long Fan (executive Director), Dr. Wu Ming (executive Director), Mr. Zhang Shen (executive Director), Mr. Zhang Yi (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director), Mr. Chen Jinzhong (independent non-executive Director), Dr. Xia Tingkan, Tim (independent non-executive Director), and Ms. Sun Sizheng (independent non-executive Director).